ArticleBMC cancer2021

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.

Young Mi Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.